Skip to main content
  • Main menu
  • User menu
  • Search
  • English ▼
    • English
    • Afrikaans
    • Albanian
    • Amharic
    • Arabic
    • Armenian
    • Azerbaijani
    • Basque
    • Belarusian
    • Bengali
    • Bosnian
    • Bulgarian
    • Catalan
    • Cebuano
    • Chichewa
    • Chinese (Simplified)
    • Chinese (Traditional)
    • Corsican
    • Croatian
    • Czech
    • Danish
    • Dutch
    • Esperanto
    • Estonian
    • Filipino
    • Finnish
    • French
    • Frisian
    • Galician
    • Georgian
    • German
    • Greek
    • Gujarati
    • Haitian Creole
    • Hausa
    • Hawaiian
    • Hebrew
    • Hindi
    • Hmong
    • Hungarian
    • Icelandic
    • Igbo
    • Indonesian
    • Irish
    • Italian
    • Japanese
    • Javanese
    • Kannada
    • Kazakh
    • Khmer
    • Korean
    • Kurdish (Kurmanji)
    • Kyrgyz
    • Lao
    • Latin
    • Latvian
    • Lithuanian
    • Luxembourgish
    • Macedonian
    • Malagasy
    • Malay
    • Malayalam
    • Maltese
    • Maori
    • Marathi
    • Mongolian
    • Myanmar (Burmese)
    • Nepali
    • Norwegian
    • Pashto
    • Persian
    • Polish
    • Portuguese
    • Punjabi
    • Romanian
    • Russian
    • Samoan
    • Scottish Gaelic
    • Serbian
    • Sesotho
    • Shona
    • Sindhi
    • Sinhala
    • Slovak
    • Slovenian
    • Somali
    • Spanish
    • Sudanese
    • Swahili
    • Swedish
    • Tajik
    • Tamil
    • Telugu
    • Thai
    • Turkish
    • Ukrainian
    • Urdu
    • Uzbek
    • Vietnamese
    • Welsh
    • Xhosa
    • Yiddish
    • Yoruba
    • Zulu

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

English ▼
  • English
  • Afrikaans
  • Albanian
  • Amharic
  • Arabic
  • Armenian
  • Azerbaijani
  • Basque
  • Belarusian
  • Bengali
  • Bosnian
  • Bulgarian
  • Catalan
  • Cebuano
  • Chichewa
  • Chinese (Simplified)
  • Chinese (Traditional)
  • Corsican
  • Croatian
  • Czech
  • Danish
  • Dutch
  • Esperanto
  • Estonian
  • Filipino
  • Finnish
  • French
  • Frisian
  • Galician
  • Georgian
  • German
  • Greek
  • Gujarati
  • Haitian Creole
  • Hausa
  • Hawaiian
  • Hebrew
  • Hindi
  • Hmong
  • Hungarian
  • Icelandic
  • Igbo
  • Indonesian
  • Irish
  • Italian
  • Japanese
  • Javanese
  • Kannada
  • Kazakh
  • Khmer
  • Korean
  • Kurdish (Kurmanji)
  • Kyrgyz
  • Lao
  • Latin
  • Latvian
  • Lithuanian
  • Luxembourgish
  • Macedonian
  • Malagasy
  • Malay
  • Malayalam
  • Maltese
  • Maori
  • Marathi
  • Mongolian
  • Myanmar (Burmese)
  • Nepali
  • Norwegian
  • Pashto
  • Persian
  • Polish
  • Portuguese
  • Punjabi
  • Romanian
  • Russian
  • Samoan
  • Scottish Gaelic
  • Serbian
  • Sesotho
  • Shona
  • Sindhi
  • Sinhala
  • Slovak
  • Slovenian
  • Somali
  • Spanish
  • Sudanese
  • Swahili
  • Swedish
  • Tajik
  • Tamil
  • Telugu
  • Thai
  • Turkish
  • Ukrainian
  • Urdu
  • Uzbek
  • Vietnamese
  • Welsh
  • Xhosa
  • Yiddish
  • Yoruba
  • Zulu
  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Watch or Listen to JNMT Podcast
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Follow SNMMI on Twitter
  • Subscribe to JNMT RSS feeds
Review ArticleContinuing Education

Guidance on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division

Amanda Abbott, Christopher G. Sakellis, Eric Andersen, Yuji Kuzuhara, Lauren Gilbert, Kelly Boyle, Matthew H. Kulke, Jennifer A. Chan, Heather A. Jacene and Annick D. Van den Abbeele
Journal of Nuclear Medicine Technology September 2018, 46 (3) 237-244; DOI: https://doi.org/10.2967/jnmt.118.209148
Amanda Abbott
1Department of Imaging and Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
MS, CNMT, RT(N)(CT), PET
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher G. Sakellis
1Department of Imaging and Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
2Department of Radiology, Brigham and Women’s Hospital, Boston, Massachusetts
3Harvard Medical School, Boston, Massachusetts
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Andersen
4Department of Environmental Health and Safety, Dana-Farber Cancer Institute, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuji Kuzuhara
1Department of Imaging and Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
MHA, RT(N)(MR)(CT)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren Gilbert
1Department of Imaging and Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
CNMT, RT(N)(CT)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelly Boyle
5Department of Adult Ambulatory Services, Nursing, and Imaging Services, Dana-Farber Cancer Institute, Boston, Massachusetts; and
MS, RN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew H. Kulke
3Harvard Medical School, Boston, Massachusetts
6Program in Neuroendocrine and Carcinoid Tumors, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer A. Chan
3Harvard Medical School, Boston, Massachusetts
6Program in Neuroendocrine and Carcinoid Tumors, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather A. Jacene
1Department of Imaging and Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
2Department of Radiology, Brigham and Women’s Hospital, Boston, Massachusetts
3Harvard Medical School, Boston, Massachusetts
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annick D. Van den Abbeele
1Department of Imaging and Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
2Department of Radiology, Brigham and Women’s Hospital, Boston, Massachusetts
3Harvard Medical School, Boston, Massachusetts
MD, FACR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Prepared dedicated treatment room (A) and restroom (B).

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    (A and B) In-house–fabricated 30-mL syringe shield (with outer-to-inner arrows indicating adhesive bandage, lead layer, and acrylic layer). (C) Supplies to draw dose (wedge, syringe shield, gauze, alcohol wipes, 30-mL and 1-mL syringes, 3.5-in [8.9-cm] spinal needle and 20-gauge needles, and chux pad).

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Dose preparation: insertion of vent needle and spinal needle for drawing up dose, with vial tilted on wedge, behind L-block in biologic safety cabinet, and with dedicated 177Lu waste bucket in back.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    Dose administration supplies: Alaris pump with amino acids, saline bag, shielded Graseby pump, and 177Lu-DOTATATE on chux pad–covered cart.

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    Amino acid/177Lu-DOTATATE infusion worksheet for technologists.

  • FIGURE 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 6.

    Amino acid/177Lu-DOTATATE infusion worksheet for nurses.

  • FIGURE 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 7.

    Dana-Farber Cancer Institute nuclear medicine team. (Back row, left to right) Umesh Mukkuzhi, MS, CNMT, RT(N)(CT), Amanda Abbott, MS, CNMT, RT(N)(CT), PET, Lauren Gilbert, CNMT, RT(N)(CT), and Timothy Belisle, CNMT, RT(N)(CT). (Middle row, left to right) Michele Iacobucci, Yuji Kuzuhara, MHA, RT(N)(MR)(CT), CNMT, Jennifer Manganella, CNMT, RT(N)(CT), and Justin Tremont, CNMT, RT(N)(CT), PET. (Front row, left to right) Christopher Sakellis, MD, Annick D. Van den Abbeele, MD, FACR, Eileen Vo, RT(N), Heather Jacene, MD, and Marta Adamkiewicz, CNMT, RT(N). (Not pictured) Theresa Carroll, RT(N)(CT), Oswaldo Delgado, CNMT, Johnny Madrid, CNMT, NMTCB(CT), James Wellemeyer, RT(N), Aida Arthur, RN, Marianne Castano, MS, RN, Marion Fallon, RN, Leslie Hajjar, RN, Betsy Mele, RN, and Mary Jane Murphy, RN.

Tables

  • Figures
    • View popup
    TABLE 1

    Staff Roles, Responsibilities, and Required Training

    Staff memberRole or responsibilityRequired training
    Medical oncology memberCommunicates with nuclear medicine team on eligible patientsWorkflow training
    Enters orders in electronic health record for 177Lu-DOTATATE procedure and required medicationsEligibility training
    Evaluates patients within week before each 177Lu-DOTATATE treatment and monitors for adverse events afterward
    PharmacistProvides antiemetics, amino acids, and posttreatment long-acting somatostatin analog on treatment dayWorkflow training
    Radiation safety officerProvides 177Lu radiation safety training to nuclear medicine staffWorkflow training
    Prepares treatment room and restroom with contamination control measures; provides radiologic survey support as needed
    Collects residual or unused doses and associated contaminated materials and manages inventory of those items for ultimate disposal
    Reviews each record of therapeutic administration
    Develops and maintains basis for release of patients after treatment
    Nuclear medicine nurseChecks electronic medical record on day before treatment to ensure medication orders have been entered correctly and sends them to pharmacy on treatment dayWorkflow and radiation safety, including patient care and waste disposal
    Places intravenous catheter in patient (can also be done by nuclear medicine technologist)Medication management and Alaris pump
    Administers antiemetics, amino acids, and long-acting somatostatin analog
    Monitors for adverse events during amino acid infusion, checks blood pressure and pulse just before and after 177Lu-DOTATATE infusion, and ensures that patient voids before and hourly after infusion
    Nuclear medicine physicianGets informed consent from patients and reviews radiation safety instructions with patientWorkflow and radiation safety
    Assays 177Lu-DOTATATE dose in dose calibrator, assesses intravenous line patency, performs time-out before infusion, and gives infusionGraseby pump
    Assesses status and discharges patient from nuclear medicine department
    Nuclear medicine technologistOrders, receives, inspects, and prepares 177Lu-DOTATATE dose for administration; prepares patient for treatment (can also be done by nurse)Workflow and radiation safety, including dose preparation and waste disposal
    Surveys restroom floor and path to treatment area with Geiger counter; contacts radiation safety officer and restricts access to contaminated areas if foundGraseby pump and 177Lu-DOTATATE dose preparation
    Prints patient dose administration card; measures exposure 1 m from patient, and confirms that level is below that established by radiation safety officer once all administrations are complete
    • View popup
    TABLE 2

    Supplies to Prepare and Administer 177Lu-DOTATATE Dose

    SupplyPurpose
    A designated treatment room and restroomTo prevent radiation exposure to other people
    Plastic-backed kraft paper and masking tapeTo line walls and floor of treatment room and bathroom
    Scrubs for patient; scrubs, lab coat, impermeable gloves, wrist gaiters, goggles or face shield, personal dosimetry badge, and radiation detection device for technologistTo monitor radiation exposure and provide personal protection
    Hot lab with L-block shield within biosafety cabinetTo prevent radiation exposure when preparing dose
    Large waste bucket for sharpsTo collect used sharps and any waste that might contain 177Lu
    WorkstationTo document medication administration and vital signs
    250-mL saline bag with extension tubingTo flush dose syringe
    3-way stopcockTo connect dose tubing and saline tubing
    22- to 20-gauge intravenous catheter system, tourniquet, chlorohexidine, Tegaderm (3M), and CoFlex adhesive bandageTo establish intravenous line
    Microbore extension tubingTo attach dose syringe to intravenous line
    10-mL prefilled saline syringeTo flush and check patency of intravenous line
    30-mL vial of salineTo train staff through simulations
    1-mL syringe, 20-gauge needleTo vent dose vial
    GauzeTo raise vial inside shielded pig and to clean area
    Chux padsTo clean and protect area
    Tongs, tweezers, and alcohol wipesTo pick up and clean vial
    30-mL lead-lined acrylic syringe shieldTo prevent radiation exposure when dose is drawn
    WedgeTo tilt vial when dose is drawn
    30-mL syringe; 20-gauge spinal needle 2.5–3.5 in (6.3–8.9 cm) longTo draw dose
    Pump and tubingTo infuse dose, as well as antiemetics and amino acids
    • View popup
    TABLE 3

    Technologist Checklist for 177Lu-DOTATATE Preparation

    Tech initialsStep
    Protect cart with chux pads
    Hang 250-mL saline bag; prime tubing with saline
    Connect tubing to 3-way stopcock; prime 3-way stopcock with saline
    Prime microbore tubing with saline; connect microbore tubing to 3-way stopcock
    Load tubing into Graseby pump
    Set rate on Graseby pump (50 mL/h); clear volume; change dose calibrator setting, sleeve, and plunger to those for 177Lu
    Label syringe with patient’s name, date of birth, medical record number, drug, dose, and date
    Assay vial (place gauze in bottom of pig while vial is still in dose calibrator), and record result and time; if less than 6.66 GBq or 180 mCi (7.4 GBq or 200 mCi − 10%), contact nuclear medicine physician before proceeding
    Draw entire dose from vial into 30-mL syringe
    Vent dose vial by attaching 20-gauge needle to 1-mL syringe (plunger removed) and inserting at tilted angle just enough to puncture vial
    Draw dose by attaching 3.5-in (8.9-cm) spinal needle to 30-mL shielded syringe, inserting into vial (tilted on wedge) until reaching its bottom, and slowly withdrawing entire volume; if withdrawal is difficult, slightly loosen thumbscrew of shield (2.5-in [6.3-cm] needle can be used but will not reach bottom)
    Before removing syringe, use tongs to raise vial and assess whether entire volume has been withdrawn
    Slowly pull syringe straight up and out of vial
    Pull back plunger to ensure that no liquid remains in hub of needle
    Discard spinal needle into sharps waste bucket; attach regular needle
    Remove air from syringe
    Assay residual activity in vial, and record result and time
    Assay syringe dose, and record result and time (nuclear medicine physician to confirm)
    Connect syringe dose to 3-way stopcock and load into Graseby pump
    After infusion, assay residual activity in syringe and needle
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 46 (3)
Journal of Nuclear Medicine Technology
Vol. 46, Issue 3
September 1, 2018
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Email Article
Citation Tools
Share
Guidance on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division
Amanda Abbott, Christopher G. Sakellis, Eric Andersen, Yuji Kuzuhara, Lauren Gilbert, Kelly Boyle, Matthew H. Kulke, Jennifer A. Chan, Heather A. Jacene, Annick D. Van den Abbeele
Journal of Nuclear Medicine Technology Sep 2018, 46 (3) 237-244; DOI: 10.2967/jnmt.118.209148
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
Bookmark this article

Jump to section

  • Article
    • Abstract
    • 177LU-DOTATATE PRRT IN BRIEF
    • ROLES OF MULTIDISCIPLINARY TEAM MEMBERS
    • ORDERING AND RECEIPT OF 177LU-DOTATATE DOSE
    • PREPARATION OF TREATMENT ROOM AND RESTROOM
    • INFUSION OF AMINO ACIDS
    • PREPARATION OF 177LU-DOTATATE DOSE
    • INFUSION OF 177LU-DOTATATE
    • FURTHER RECOMMENDATIONS
    • CONCLUSION
    • DISCLOSURE
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • 177Lu-Dotatate administration using an infusion pump or a peristaltic pump: comparison of two methods
  • A Rapid and Safe Infusion Protocol for 177Lu Peptide Receptor Radionuclide Therapy
  • Google Scholar

More in this TOC Section

  • Illuminating the Hidden: Standardizing Cardiac MIBG Imaging for Sympathetic Dysfunction
  • PET/CT Case Series: Unmasking the Mystery of Cardiac Sarcoidosis
  • Delivery Methods of Radiopharmaceuticals: Exploring Global Strategies to Minimize Occupational Radiation Exposure
Show more Continuing Education

Similar Articles

Keywords

  • Radionuclide Therapy
  • peptide receptor radionuclide therapy (PRRT)
  • nuclear medicine
  • 177Lu-DOTATATE
  • neuroendocrine tumor
SNMMI

© 2025 SNMMI

Powered by HighWire
Alerts for this Article
Sign In to Email Alerts with your Email Address
Email this Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Guidance on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
Guidance on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division
Amanda Abbott, Christopher G. Sakellis, Eric Andersen, Yuji Kuzuhara, Lauren Gilbert, Kelly Boyle, Matthew H. Kulke, Jennifer A. Chan, Heather A. Jacene, Annick D. Van den Abbeele
Journal of Nuclear Medicine Technology Sep 2018, 46 (3) 237-244; DOI: 10.2967/jnmt.118.209148

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

We use cookies on this site to enhance your user experience

By clicking any link on this page you are giving your consent for us to set cookies.